daptomycin (up to 14 days) — Competitive Intelligence Brief

daptomycin (up to 14 days) (daptomycin (up to 14 days)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cyclic lipopeptide antibiotic. Area: Infectious Disease.

marketed Cyclic lipopeptide antibiotic Bacterial cell membrane Infectious Disease Small molecule

Target snapshot

daptomycin (up to 14 days) (daptomycin (up to 14 days)) — Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Daptomycin binds to bacterial cell membranes and causes rapid depolarization, leading to loss of essential ions and bacterial cell death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
daptomycin (up to 14 days) TARGET	daptomycin (up to 14 days)	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	marketed	Cyclic lipopeptide antibiotic	Bacterial cell membrane
Silvadene	Silver Sulfadiazine	Pfizer	marketed	sulfonamide antimicrobial	bacterial cell membrane and cell wall	1973-01-01
Chlorhexidine 0.06% mouthrinse	Chlorhexidine 0.06% mouthrinse	University of Oslo	marketed	Antimicrobial oral rinse	Bacterial cell membrane and proteins
Adapalene/benzoyl peroxide gel, 0.1%/2.5%	Adapalene/benzoyl peroxide gel, 0.1%/2.5%	Galderma R&D	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
chlorhexidine digluconate	chlorhexidine digluconate	Universidade Federal do Ceara	marketed	Antimicrobial agent / Antiseptic	Bacterial cell membrane and proteins
Polysporin Triple	Polysporin Triple	University Health Network, Toronto	marketed	Topical antibiotic combination	Bacterial cell wall (bacitracin), bacterial ribosome (neomycin), bacterial cell membrane (polymyxin B)
Ceftazidime-avibactam + Colistin/Polymyxin B	Ceftazidime-avibactam + Colistin/Polymyxin B	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor + polymyxin antibiotic combination	Bacterial peptidoglycan cross-linking enzymes (PBPs); beta-lactamases; bacterial cell membrane lipopolysaccharide and phospholipids

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cyclic lipopeptide antibiotic class)

1. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
2. Todd C. Lee MD MPH FIDSA · 1 drug in this class